Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Mishra RK et al. | Differential dependence of eosinophil chemotactic responses on phosphoinositide 3-kinase (PI3K). | 2005 | Allergy | pmid:16076309 |
Schauer U et al. | Enhanced production of platelet activating factor by peripheral granulocytes from children with asthma. | 1992 | Allergy | pmid:1514664 |
Egesten A and Malm J | Eosinophil leukocyte degranulation in response to serum-opsonized beads: C5a and platelet-activating factor enhance ECP release, with roles for protein kinases A and C. | 1998 | Allergy | pmid:9860239 |
Woo HY et al. | Mechanism for acute oral desensitization to antibiotics. | 2006 | Allergy | pmid:16867049 |
Howarth PH | Mediators of nasal blockage in allergic rhinitis. | 1997 | Allergy | pmid:9353555 |
Zuberbier T et al. | Histamine releasability of basophils and skin mast cells in chronic urticaria. | 1996 | Allergy | pmid:8721524 |
Zeck-Kapp G et al. | Mechanisms of human eosinophil activation by complement protein C5a and platelet-activating factor: similar functional responses are accompanied by different morphologic alterations. | 1995 | Allergy | pmid:7741187 |
Krause K et al. | Platelet-activating factor (PAF) induces wheal and flare skin reactions independent of mast cell degranulation. | 2013 | Allergy | pmid:23320562 |
Bachert C | Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. | 2001 | Allergy | pmid:11243500 |
Mullol J et al. | Rupatadine in allergic rhinitis and chronic urticaria. | 2008 | Allergy | pmid:18339040 |
Pipkorn U et al. | Effect of platelet activating factor on the human nasal mucosa. | 1984 | Allergy | pmid:6703263 |
Takafuji S et al. | Effects of interleukin (IL)-3 and IL-5 on human eosinophil degranulation induced by complement components C3a and C5a. | 1996 | Allergy | pmid:8874660 |
Soyombo O et al. | Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. | 1994 | Allergy | pmid:8037356 |
Takafuji S et al. | Release of granule proteins from human eosinophils stimulated with mast-cell mediators. | 1998 | Allergy | pmid:9821474 |
Maniscalco M et al. | The effect of platelet-activating factor (PAF) on nasal airway resistance in healthy subjects is not mediated by nitric oxide. | 2000 | Allergy | pmid:10955702 |
Mukai K et al. | New insights into the roles for basophils in acute and chronic allergy. | 2009 | Allergol Int | pmid:19153532 |
Negro Alvarez JM et al. | Platelet-activating factor antagonists. | 1997 Sep-Oct | Allergol Immunopathol (Madr) | pmid:9395010 |
MonteseirÃn J et al. | Formation of lipids, peptides and cytokines. | 1996 Sep-Oct | Allergol Immunopathol (Madr) | pmid:8985477 |
Miadonna A et al. | Induction and control of allergic inflammation in human respiratory airways. | 1993 May-Jun | Allergol Immunopathol (Madr) | pmid:7689291 |
Rihoux JP | [Allergic reaction and vascular permeability]. | 1990 | Allerg Immunol (Paris) | pmid:2288644 |
Beauvais F and Benveniste J | [IgE and anaphylaxis mediators]. | 1987 | Allerg Immunol (Paris) | pmid:2968802 |
Mencia-Huerta JM et al. | [Effect of long-term administration of platelet activating factor on pulmonary response and morphology in the guinea pig]. | 1988 | Allerg Immunol (Paris) | pmid:3245884 |
Ligumsky M et al. | The role of platelet activating factor [correction of actor] in acute gastric injury and its protection by sucralfate. | 1990 | Aliment. Pharmacol. Ther. | pmid:2129638 |
Greenberg SS et al. | Ethanol suppresses endotoxin but not platelet activating factor-induced hypotension and nitric oxide. | 1996 | Alcohol. Clin. Exp. Res. | pmid:8904980 |
Saleh AA et al. | Effect of alcohol on platelet-activating factor acetylhydrolase activity in pregnant and nonpregnant mice. | 1994 | Alcohol. Clin. Exp. Res. | pmid:7978079 |
Baker RC et al. | Effects of ethanol on human platelets stimulated with platelet-activating factor, a biologically active ether phospholipid. | 1989 | Alcohol. Clin. Exp. Res. | pmid:2557776 |
Lands WE | Cellular signals in alcohol-induced liver injury: a review. | 1995 | Alcohol. Clin. Exp. Res. | pmid:7485841 |
Kelesidis T et al. | The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection. | AIDS Rev | pmid:26616844 | |
Chini M et al. | Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen. | 2012 | AIDS Res. Hum. Retroviruses | pmid:22050695 |
Lima RG et al. | Interaction of macrophages with apoptotic cells enhances HIV Type 1 replication through PGE2, PAF, and vitronectin receptor. | 2006 | AIDS Res. Hum. Retroviruses | pmid:16910832 |
Tsoupras AB et al. | Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? | 2008 | AIDS Res. Hum. Retroviruses | pmid:18620493 |
Bertrand C et al. | Selective implication of thromboxane A2 and PAF-acether in two guinea pig anaphylactic models. | 1990 | Agents Actions Suppl. | pmid:2080755 |
Tsunoda H et al. | Effects of a novel PAF antagonist, E6123, on PAF-induced biological responses. | 1990 | Agents Actions Suppl. | pmid:2080757 |
Sakuma Y et al. | Effects of a novel PAF antagonist, E6123, on passive anaphylaxis. | 1990 | Agents Actions Suppl. | pmid:2080758 |
Kurosawa M | Effect of platelet activating factor on histamine release from rat mast cells. | 1987 | Agents Actions Suppl. | pmid:2445185 |
Alabaster VA et al. | UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. | 1991 | Agents Actions Suppl. | pmid:1793066 |
Heuer HO | The effects of hetrazepine PAF antagonists in preclinical models of asthma. | 1991 | Agents Actions Suppl. | pmid:1793067 |
Mazzoni L et al. | Changes in airway sensitivity to histamine are not necessarily paralleled by changed sensitivity to acetylcholine. | 1991 | Agents Actions Suppl. | pmid:1793069 |
Billah MM et al. | Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. | 1991 | Agents Actions Suppl. | pmid:1793070 |
Saeed SA et al. | Inhibitory effect of oral ketotifen on ex vivo platelet activating factor-induced platelet aggregation. | 1991 | Agents Actions Suppl. | pmid:1793071 |
Anderson GP and Fennessy MR | Lipoxygenase metabolites as mediators of platelet activating factor-induced increased airways responsiveness to histamine in the guinea-pig. | 1988 | Agents Actions Suppl. | pmid:3140616 |
Page CP et al. | Drugs affecting pulmonary responses to platelet activating factor as novel anti-asthma drugs. | 1988 | Agents Actions Suppl. | pmid:3051932 |
Muirhead EE | Vasodepressor lipid of the renomedullary interstitial cells of the renal papilla is a prohormone activated by the liver. | 1987 | Agents Actions Suppl. | pmid:3324720 |
Mest HJ et al. | Effect of BN 52256 and other mediator antagonists on ouabain-induced ventricular fibrillation in sensitized guinea-pigs and on ischemia-induced fibrillation in rats. | 1992 | Agents Actions Suppl. | pmid:1632298 |
Koltai M and Braquet PG | Involvement of PAF in atherogenesis. Brief review. | 1992 | Agents Actions Suppl. | pmid:1632308 |
Subissi A and Criscuoli M | Effects of LG 30435 on different platelet activating factor-induced responses. | 1988 | Agents Actions Suppl. | pmid:3262990 |
Heuer H and Casals-Stenzel J | Effect of the PAF-antagonist WEB 2086 on anaphylactic lung reaction: comparison of inhalative and intravenous challenge. | 1988 | Agents Actions Suppl. | pmid:3262991 |
McMillan RM and Carter GW | Design and development of drugs. | 1991 | Agents Actions Suppl. | pmid:1664186 |
Stenzel H et al. | Effect of the PAF-antagonist SRI 63-441 on the allergic reaction in awake dogs with natural asthma. | 1987 | Agents Actions Suppl. | pmid:2823582 |
Etienne A et al. | Antithrombotic activity of BN 50341, a structurally new compound with anticalcic and PAF-antagonistic properties. | 1986 | Agents Actions Suppl. | pmid:3468781 |